GlassScriptPhysician profile
Kami M Dever
NPI 1801823562
$4,333.21
in general payments reported to CMS, 2019-2025
32 companies · $900 in 2025
The $900 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $924 · 2023: $1,026 · 2024: $995 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $677.61 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $474.85 | 2021-2025 | Jot Dx, Aveir, Gallant |
| Novartis Pharmaceuticals Corporation | $399.49 | 2021-2024 | |
| Aop Health US, LLC | $338.60 | 2025 | Rapiblyk |
| Medtronic, INC. | $228.96 | 2021-2025 | Cobalt Dr Mri Surescan, Micra, Azure Xt Dr Mri Surescan |
| Pfizer INC. | $208.87 | 2022-2025 | |
| Amgen INC. | $190.81 | 2022-2025 | Repatha |
| Inari Medical, INC. | $186.20 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $175.99 | 2022-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.38 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $168.12 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $132.93 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $129.92 | 2021-2025 | Farxiga, Brilinta |
| Scpharmaceuticals INC. | $117.26 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.60 | 2021-2023 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $83.94 | 2024-2025 | Barostim Neo System |
| Tactile Systems Technology INC | $62.74 | 2023 | Flexitouch Plus, Entre Plus |
| Bayer Healthcare Pharmaceuticals INC. | $62.36 | 2025 | |
| Esperion Therapeutics, INC. | $57.80 | 2021-2024 | Nexletol |
| Edwards Lifesciences Corporation | $43.87 | 2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $40.78 | 2022 | |
| Innovation Technologies INC | $39.59 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $34.61 | 2023 | Arcalyst |
| Heartflow, INC. | $32.26 | 2025 | |
| Boston Scientific Corporation | $32.09 | 2025 | Watchman Flx |
| Inspire Medical Systems, INC. | $25.22 | 2024 | Inspire |
| Medicomp INC | $22.38 | 2025 | Telepatch Cardiac Monitor |
| Stryker Corporation | $22.17 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Irhythm Technologies, INC. | $20.25 | 2022 | |
| Novo Nordisk INC | $17.53 | 2024 | Rybelsus, Ozempic |
| Angiodynamics, INC. | $14.78 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $13.25 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kami Dever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.